Influence of Donor Type (Sibling versus Matched Unrelated Donor versus Haploidentical Donor) on Outcomes after Clofarabine-Based Reduced-Intensity Conditioning Allograft for Myeloid Malignancies

Haploidentical stem cell transplantations using high-dose post-transplant cyclophosphamide (PTCY) are increasingly used in patients lacking suitable matched donors [1]. The Baltimore reduced-intensity conditioning (RIC) regimen, combining fludarabine, low doses of cyclophosphamide and total body irradiation, followed by PCTY, has become a standard of care in this setting in some institutions [2]. Recently we reported the encouraging results of a “Clo-Baltimore” RIC regimen for myeloid malignancies where fludarabine was replaced by clofarabine and bone marrow by peripheral blood stem cells (PBSCs) as the source of graft [3].

Source: Biology of Blood and Marrow Transplantation - March 26, 2019 Category: Hematology Authors: Louise Bouard, Thierry Guillaume, Pierre Peterlin, Alice Garnier, Amandine Le Bourgeois, Alix Duquenne, Beatrice Mahe, Viviane Dubruille, Nicolas Blin, Cyrille Touzeau, Thomas Gastinne, Yannick Le Bris, Anne Lok, Antoine Bonnet, Steven Le Gouill, Philippe Source Type: research